Golgi-protein 73 facilitates vimentin polymerization in hepatocellular carcinoma

Xinyang Hu, Shijin Yuan, Sining Zhou, Ting Sun, Chaoqun Wang, Shilong Ying, Heping Zhu, Jingfeng Luo, Hongchuan Jin, Yiming LiuInternational Journal of Biological Sciences 2023 · DOI

Abstract

Golgi-protein 73 (GP73) is highly expressed in hepatocellular carcinoma (HCC) and serves as a secretory biomarker for disease progression. This study identifies a novel functional role for GP73 in promoting HCC metastasis by interacting with vimentin. GP73 facilitates PP1A-mediated dephosphorylation of vimentin at Serine 56, promoting its polymerization. This polymerization effectively shields vimentin from TRIM56-mediated ubiquitin/proteasome-dependent degradation, stabilizing the mesenchymal cytoskeleton. Furthermore, the antidepressant Clomipramine was identified as a potent inhibitor of GP73-mediated vimentin polymerization, significantly reducing metastasis in vivo. These findings establish GP73 as a key regulator of vimentin stability and suggest that serum GP73 (sGP73) can serve as a companion diagnostic for vimentin-targeted therapies in metastatic HCC.

Introduction

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, primarily due to its high rate of metastasis. Golgi-protein 73 (GP73) has long been used as a serum biomarker for HCC, but its functional role in cancer spread remained poorly defined. Metastasis is often driven by the Epithelial-Mesenchymal Transition (EMT), where vimentin plays a critical role in providing structural integrity to migratory cells. This research investigates how GP73 regulates vimentin to fuel HCC progression.

Methods and Discovery

To identify GP73's molecular partners, researchers used LC-MS/MS proteomics, which pinpointed vimentin as a key interactor. This was confirmed through Co-Immunoprecipitation (Co-IP) assays.

Identification of vimentin as a GP73-interacting protein.

The study also employed Structural Illumination Microscopy (SIM) for high-resolution imaging of vimentin filaments and biochemical assays to analyze polymerization states. Molecular docking was used to screen FDA-approved compounds for their ability to disrupt vimentin assembly.

Results

The GP73-Vimentin-PP1A Axis

GP73 acts as a scaffold that recruits the phosphatase PP1A to dephosphorylate vimentin at S56. This dephosphorylation is the key trigger for vimentin polymerization. Crucially, polymerization protects vimentin from being targeted by the E3 ubiquitin ligase TRIM56, which can only degrade monomeric vimentin. Thus, GP73 stabilizes the vimentin network by "shielding" it from the proteasome.

Functional Impact and Therapeutic Targeting

Functional assays demonstrated that GP73 expression is essential for vimentin-mediated cell migration. In metastatic HCC cell lines, silencing GP73 significantly impaired migration.

GP73 promotes cell migration through vimentin stabilization.

Screening identified Clomipramine, an FDA-approved antidepressant and 5-HTR agonist, as a potent inhibitor of vimentin polymerization. In mouse models, Clomipramine effectively reduced lung metastasis and showed synergistic effects when combined with the standard drug Sorafenib.

Clinical Significance

In patient cohorts, GP73 and vimentin levels showed a strong positive correlation ($r = 0.7440$), and high expression of both was linked to poor survival. Serum GP73 (sGP73) levels effectively predicted high tissue vimentin (AUC = 0.8048), suggesting its utility as a companion diagnostic tool.

Discussion

This study elucidates a novel mechanism where GP73 stabilizes vimentin to promote HCC metastasis. The discovery that Clomipramine can disrupt this process provides a promising avenue for drug repurposing in cancer therapy. While further clinical trials are needed, the correlation between serum GP73 and tissue vimentin offers a practical method for identifying patients who might benefit from these targeted interventions.

Summary updated

Abstract

Golgi-protein 73 (GP73) is highly expressed in hepatocellular carcinoma (HCC) and, as a secretory protein, it has been proposed as a serum biomarker indicating progression of HCC. The underlying mechanism by which GP73 may promote HCC metastasis is still poorly understood. In this study, we discovered that GP73 interacted with vimentin to facilitate Serine/Threonine-protein phosphatase PP1-alpha (PP1A)-mediated dephosphorylation of vimentin at S56 and facilitated vimentin polymerization, which blocked vimentin degradation via TRIM56-mediated ubiquitin/proteasome-dependent pathway. Strikingly, Clomipramine, a 5-hydroxytryptamine receptor (5-HTR) agonist approved for the treatment of depression, impaired GP73-mediated vimentin polymerization to effectively inhibit metastasis of HCC with high GP73 expression, which provided a new strategy against HCC metastasis. Lastly, it was found that serum GP73 (sGP73) correlated positively with vimentin in primary tissues of HCC, suggesting that sGP73 might serve as a potential serum biomarker for companion diagnosis of HCC with highly expressed vimentin. In summary, this study reveals the process of GP73-mediated vimentin polymerization and proves that Clomipramine serves as a potential drug targeting vimentin for metastatic HCC patients with high sGP73 level.
BibTeX
@article{hu2023golgi,
  author = {Xinyang Hu and Shijin Yuan and Sining Zhou and Ting Sun and Chaoqun Wang and Shilong Ying and Heping Zhu and Jingfeng Luo and Hongchuan Jin and Yiming Liu},
  title = {{Golgi-protein 73 facilitates vimentin polymerization in hepatocellular carcinoma}},
  journal = {International Journal of Biological Sciences},
  year = {2023},
  doi = {10.7150/ijbs.85431},
}
Figure